| Symbol | NXL |
|---|---|
| Name | NEXALIN TECHNOLOGY, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Address | 1776 YORKTOWN,SUITE 550, HOUSTON, Texas, 77056, United States |
| Telephone | +1 832 - 260-0222 |
| Fax | — |
| — | |
| Website | https://www.nexalin.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001527352 |
| Description | Nexalin Technology Inc design and develop innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. Additional info from NASDAQ: |
New Form PRE 14A - Nexalin Technology, Inc. <b>Filed:</b> 2026-06-29 <b>AccNo:</b> 0001829126-26-007001 <b>Size:</b> 2 MB
Read moreNexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company’s Proprietary DIFS™ Platform
Read moreNexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life
Read moreNexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan.
Read moreNexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia
Read moreNexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury
Read more(80% Positive) NEXALIN TECHNOLOGY, INC. (NXL) Announces Enrollment Update for developed Due to Patient Enrollment Issues, Regulatory Process, Safety Review
Read moreNexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial
Read moreNexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07659366 | HALO Clarity™ Cranial Alternating Current Stimulation Therapy for Adults With M… | Na | Moderate to Severe Insomnia | Not_Yet_Recruiting | 2026-06-22 | 2027-10-25 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Transcranial alternating current stimulator | Other | Approved | Moderate to Severe Insomnia | NOT_YET_RECRUITING | NCT07659366 |